Stephen Liu: Proud to be Part of the Team Behind the Phase III IMforte trial
Stephen Liu, Associate Professor of Medicine at Georgetown University, posted on LinkedIn:
“Proud to be part of the team behind the phase III IMforte trial. This is the first phase 3 maintenance study in SCLC to show a survival benefit with an OS HR 0.73 – small cell lung cancer is an unforgiving disease and this strategy will allow patients to have a chance at extended survival.
Presentation at ASCO25 and simultaneous publication in the Lancet. Thanks to the whole team that helped make this happen.”
Title: Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Authors: Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, Solange Peters, Roy S Herbst, Katarzyna Stencel, Margarita Majem, Mehmet Ali Nahit Şendur, Grzegorz Czyżewicz, Reyes Bernabé Caro, Ki Hyeong Lee, Melissa L Johnson, Nuri Karadurmuş, Christian Grohé, Sofia Baka, Tibor Csőszi, Jin Seok Ahn, Raffaele Califano, Tsung-Ying Yang, Yasemin Kemal, Marcus Ballinger, Vaikunth Cuchelkar, Vilma Graupner, Ya-Chen Lin, Debasis Chakrabarti, Kamalnayan Bhatt, George Cai, Robert Iannone, Martin Reck
Read The Full Article at The Lancet.
More posts featuring Stephen V Liu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023